LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

TG Therapeutics Inc

Fechado

SetorSaúde

32.14 -0.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

31.54

Máximo

32.55

Indicadores-chave

By Trading Economics

Rendimento

23M

28M

Vendas

20M

141M

P/E

Médio do Setor

85.211

35.664

Margem de lucro

19.97

Funcionários

370

EBITDA

25M

38M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+0.65% upside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

578M

5.1B

Abertura anterior

32.79

Fecho anterior

32.14

Sentimento de Notícias

By Acuity

30%

70%

102 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

TG Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de set. de 2025, 22:41 UTC

Grandes Movimentos do Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 de set. de 2025, 16:04 UTC

Grandes Movimentos do Mercado

Upexi Shares Climb on Solana Gains

12 de set. de 2025, 15:03 UTC

Grandes Movimentos do Mercado

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 de set. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

12 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de set. de 2025, 20:09 UTC

Ganhos

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 de set. de 2025, 19:23 UTC

Conversa de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 de set. de 2025, 19:16 UTC

Conversa de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 de set. de 2025, 19:03 UTC

Conversa de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 de set. de 2025, 18:59 UTC

Conversa de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 de set. de 2025, 18:38 UTC

Conversa de Mercado
Ganhos

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 de set. de 2025, 18:33 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 de set. de 2025, 18:22 UTC

Conversa de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 de set. de 2025, 16:56 UTC

Conversa de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 de set. de 2025, 16:22 UTC

Ganhos

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 de set. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de set. de 2025, 16:19 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

12 de set. de 2025, 16:11 UTC

Ganhos

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 de set. de 2025, 15:37 UTC

Conversa de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 de set. de 2025, 15:22 UTC

Conversa de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 de set. de 2025, 15:07 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 de set. de 2025, 14:34 UTC

Conversa de Mercado

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 de set. de 2025, 14:10 UTC

Conversa de Mercado

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 de set. de 2025, 13:58 UTC

Conversa de Mercado

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 de set. de 2025, 13:58 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 de set. de 2025, 13:57 UTC

Ganhos

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 de set. de 2025, 13:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 de set. de 2025, 13:56 UTC

Conversa de Mercado

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 de set. de 2025, 13:54 UTC

Conversa de Mercado

U.S. Natural Gas Recovers Ground -- Market Talk

Comparação entre Pares

Variação de preço

TG Therapeutics Inc Previsão

Preço-alvo

By TipRanks

0.65% parte superior

Previsão para 12 meses

Média 32.67 USD  0.65%

Máximo 50 USD

Mínimo 11 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para TG Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

3 ratings

1

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 34.86Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

102 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat